Cargando…

SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies

Patients with hematologic conditions have a higher risk of severe COVID-19 and COVID-19-related death. This is related to immune deficiencies induced by hematologic conditions and/or the treatment thereof. Prospective vaccine immunogenicity studies have demonstrated that in the majority of patients,...

Descripción completa

Detalles Bibliográficos
Autores principales: Haggenburg, Sabine, Hofsink, Quincy, Rutten, Caroline E., Nijhof, Inger S., Hazenberg, Mette D., Goorhuis, Abraham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674560/
https://www.ncbi.nlm.nih.gov/pubmed/36805887
http://dx.doi.org/10.1053/j.seminhematol.2022.11.001
_version_ 1784833182029316096
author Haggenburg, Sabine
Hofsink, Quincy
Rutten, Caroline E.
Nijhof, Inger S.
Hazenberg, Mette D.
Goorhuis, Abraham
author_facet Haggenburg, Sabine
Hofsink, Quincy
Rutten, Caroline E.
Nijhof, Inger S.
Hazenberg, Mette D.
Goorhuis, Abraham
author_sort Haggenburg, Sabine
collection PubMed
description Patients with hematologic conditions have a higher risk of severe COVID-19 and COVID-19-related death. This is related to immune deficiencies induced by hematologic conditions and/or the treatment thereof. Prospective vaccine immunogenicity studies have demonstrated that in the majority of patients, a 3-dose COVID-19 vaccination schedule leads to antibody concentrations comparable to levels obtained in healthy adults after a 2-dose schedule. In B cell depleted patients, humoral responses are poor, however vaccination did induce potent cellular immune responses. The effect of 3-dose vaccination schedules and COVID-19 booster vaccinations on the protection of patients with hematologic malignancies against severe COVID-19 and COVID-19 related death remains to be confirmed by population-based vaccine effectiveness studies.
format Online
Article
Text
id pubmed-9674560
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Author(s). Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-96745602022-11-21 SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies Haggenburg, Sabine Hofsink, Quincy Rutten, Caroline E. Nijhof, Inger S. Hazenberg, Mette D. Goorhuis, Abraham Semin Hematol Article Patients with hematologic conditions have a higher risk of severe COVID-19 and COVID-19-related death. This is related to immune deficiencies induced by hematologic conditions and/or the treatment thereof. Prospective vaccine immunogenicity studies have demonstrated that in the majority of patients, a 3-dose COVID-19 vaccination schedule leads to antibody concentrations comparable to levels obtained in healthy adults after a 2-dose schedule. In B cell depleted patients, humoral responses are poor, however vaccination did induce potent cellular immune responses. The effect of 3-dose vaccination schedules and COVID-19 booster vaccinations on the protection of patients with hematologic malignancies against severe COVID-19 and COVID-19 related death remains to be confirmed by population-based vaccine effectiveness studies. The Author(s). Published by Elsevier Inc. 2022-10 2022-11-19 /pmc/articles/PMC9674560/ /pubmed/36805887 http://dx.doi.org/10.1053/j.seminhematol.2022.11.001 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Haggenburg, Sabine
Hofsink, Quincy
Rutten, Caroline E.
Nijhof, Inger S.
Hazenberg, Mette D.
Goorhuis, Abraham
SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies
title SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies
title_full SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies
title_fullStr SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies
title_full_unstemmed SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies
title_short SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies
title_sort sars-cov-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674560/
https://www.ncbi.nlm.nih.gov/pubmed/36805887
http://dx.doi.org/10.1053/j.seminhematol.2022.11.001
work_keys_str_mv AT haggenburgsabine sarscov2vaccineinducedhumoralandcellularimmunityinpatientswithhematologicmalignancies
AT hofsinkquincy sarscov2vaccineinducedhumoralandcellularimmunityinpatientswithhematologicmalignancies
AT ruttencarolinee sarscov2vaccineinducedhumoralandcellularimmunityinpatientswithhematologicmalignancies
AT nijhofingers sarscov2vaccineinducedhumoralandcellularimmunityinpatientswithhematologicmalignancies
AT hazenbergmetted sarscov2vaccineinducedhumoralandcellularimmunityinpatientswithhematologicmalignancies
AT goorhuisabraham sarscov2vaccineinducedhumoralandcellularimmunityinpatientswithhematologicmalignancies